This is an open-label, phase 1, dose-escalation, multicenter trial evaluating the safety of oncolytic adenovirus TILT-123 as monotherapy in advanced solid tumor patients.

Principal investigator: Katriina Peltola
Trial site: HUS Comprehensive Cancer Center